CYANOPHY Laboratoire SAS: Convertible bond 2024-27 now open for subscription

Aix-en-Provence (pta016/06.08.2024/10:00 UTC+2)

Since 31 July 2024, the convertible bond of CYANOPHY Laboratoire SAS (CL) can be subscribed. With the creation of the uncertificated securities (i.e. the convertible bond in denominations of EUR 100,000 each, nominal value) at SIX SIS Group Switzerland, the Central Securities Depository (CSD) of the Swiss financial market and International Central Securities Depository (ICSD), the company has taken the final step towards the issue on the MTF Bond of the Vienna Stock Exchange. As already announced in the press release of 15 July 2024, Bendura Bank AG, has been mandated by CL as paying agent for the bond.

Information on the convertible bond was already announced in the last press release but is listed next again:

Issuer: CYANOPHY Laboratoire SAS
- Listing: Vienna Stock Exchange, MTF segment
- ISIN Code: CH1365761050
- Amount of the bond issue ("uncertificated securities"): 30 million euros
- Term of the issue: 3 years
- Minimum investment amount: 100,000 euros (or a multiple)
- Interest rate: 5% per annum
- Repayment: Capital at maturity (at 100% nominal value of convertible bond)
- Conversion possible at any time during the term of the bond, conversion price conditioned by "incentive" conversion:

• Year 1 (2025): EUR 100,000 converted into 833 shares (20% discount, conversion price per share: EUR 120.00)
• Year 2 (2026): EUR 100,000 converted into 741 shares (10% discount, conversion price per share: EUR 135.00)
• End of term (2027): EUR 100,000 converted into 667 shares (0% discount, conversion price per share: EUR 150.00)

- Interest payment: Annually
- Nominal value per CL share: EUR 20

Contact
Investors, media and analyst enquiries should contact:
Harald Gruber
Investor Relations Manager (IR), CYANOPHY Laboratoire SAS
Phone: +41 79 897 71 84
E-mail: gruber@gruberconsult.ch

About CYANOPHY Laboratoire SAS
CYANOPHY Laboratoire SAS is a leading company for innovations in cell health. Its product portfolio comprises high-purity extracts for cultivating the microalgae phycocyanin and astaxanthin.

These purely natural active ingredients have particularly pronounced antioxidant and anti-inflammatory properties. The health effects are especially highly effective on humans.

Thanks to the company's know-how (IP) and the application of the proprietary technology eco-extraction (spirulina is processed into the high-value end product phycocyanin), as well as the subsequent transformation into the liposomal form of administration (currently phycocyanin, later also astaxanthin), CYANOPHY Laboratoire's products offer unrivalled stability and efficiency.

As a result, CYANOPHY Laboratoire occupies a unique position in the microalgae market. The company's mission is to offer industrial solutions for maintaining and improving cellular health, combined with nature-based, environmentally friendly manufacturing processes. This business model enables successful marketing of the active ingredients featuring unassailed merits: highest efficacy rate, avoiding problems inherent in synthetic products.

For further informations about the company: https://cyanophy.com

(end)

Emitter:	CYANOPHY Laboratoire SAS Les Carrés de L'enfant - Bâtiment E - Avenue du 12 Juillet 1998 13080 Aix-en-Provence France
Contact Person:	Harald Gruber, Investor Relations Manager (IR)
Phone:	+41 79 897 71 84
E-Mail:	gruber@gruberconsult.ch
Website:	www.cyanophy.com
ISIN(s):	CH1365761050 (Bond)
Stock Exchange(s):	Vienna Stock Exchange (Vienna MTF)